Watchlist Price Alert

Replimune Group Inc. (REPL)

NASDAQ: REPL · Real-Time Price · USD

9.88

0.10 (1.02%)

At close: Jun 16, 2025, 3:59 PM

9.90

0.25%

After-hours: Jun 16, 2025, 07:21 PM EDT

1.02% (1D)

Bid	9
Market Cap	761.23M
Revenue (ttm)	n/a
Net Income (ttm)	-247.3M
EPS (ttm)	-3.04
PE Ratio (ttm)	-3.25
Forward PE	-3.34
Analyst	Buy

Ask	10.88
Volume	584,739
Avg. Volume (20D)	1,167,084
Open	9.69
Previous Close	9.78
Day's Range	9.68 - 10.00
52-Week Range	6.44 - 17.00
Beta	0.61

About REPL

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol REPL

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for REPL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

+6.57%

Replimune Group shares are trading higher after th... Unlock content with Pro Subscription

4 months ago

+9.87%

Replimune Group shares are trading higher after HC Wainwright & Co. and BMO Capital raised their respective price targets on the stock.

News

3 weeks ago · seekingalpha.com

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

Replimune Group, Inc. (NASDAQ:REPL ) Q4 2025 Results Conference Call May 22, 2025 8:00 AM ET Company Participants Arleen Goldenberg - Senior Communications Leader Sushil Patel - Chief Executive Office...

1 month ago · seekingalpha.com

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Replimune Group, Inc.'s BLA of RP1 + OPDIVO in advanced melanoma received an FDA Priority Review, with a PDUFA date set for July 22, 2025. RP2, adding an anti-CTLA-4 component, is being tested in meta...